• Shire plc, of Dublin, inked an exclusive distribution and supply agreement for Prasco Laboratories, of Cincinnati, to market an authorized generic version of Fosrenol (lanthanum carbonate) chewable tablets. Fosrenol is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease.